Trials
2 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol”In the company’s words, NCT07198633 on ClinicalTrials.gov
- Tested for
- Advanced Prostate Cancer, Prostatic Neoplasms
- Main trialPhase 1/2
- “This study is an open-label, multicenter Phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of QLC5508 in combination with NHA (abiraterone or enzalutamide), QLC5508 in combination with QLH12016, QLC5508 in combination with QLH12016 and NHA (abiraterone or enzalutamide), and QLH12016 in combination with NHA (abiraterone or enzalutamide) in subjects with advanced prostate cancer. The study consists of two stages: Phase Ib: is the combination dose-escalation stage, during which the recommended Phase II dose (RP2D)…”In the company’s words, NCT07198633 on ClinicalTrials.gov
Other drugs for Advanced Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up2
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2026 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | |
| Phase 1/2Not yet recruiting | Oct 2027 | Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer | |
| Phase 1Unknown | 31 Aug 2025 | Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026